These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35967384)

  • 1. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.
    Liu L; Liu Z; Gao J; Liu X; Weng S; Guo C; Hu B; Wang Z; Zhang J; Shi J; Guo W; Zhang S
    Front Immunol; 2022; 13():964190. PubMed ID: 35967384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma.
    Hu B; Gao J; Shi J; Zhang F; Shi C; Wen P; Wang Z; Guo W; Zhang S
    Front Immunol; 2022; 13():970117. PubMed ID: 35967375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cellular trajectories of tumor-associated macrophages decipher the heterogeneity of pancreatic cancer.
    Lin J; Lu F; Wu Y; Huang H; Pan Y
    Funct Integr Genomics; 2023 Nov; 23(4):343. PubMed ID: 37991591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bulk and single-cell transcriptome reveal the immuno-prognostic subtypes and tumour microenvironment heterogeneity in HCC.
    Ji D; Lu S; Zhang H; Li Z; Wang S; Miao T; Jiang Z; Ao L
    Liver Int; 2024 Apr; 44(4):979-995. PubMed ID: 38293784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
    Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
    Yu X; Chen P; Yi W; Ruan W; Xiong X
    Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis.
    Zhang Y; Qin N; Wang X; Liang R; Liu Q; Geng R; Jiang T; Liu Y; Li J
    Oncol Res; 2024; 32(3):563-576. PubMed ID: 38361757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
    Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
    Hong W; Zhang Y; Wang S; Zheng D; Hsu S; Zhou J; Fan J; Zeng Z; Wang N; Ding Z; Yu M; Gao Q; Du S
    Cancer Lett; 2024 Feb; 582():216594. PubMed ID: 38135208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stemness Refines the Classification of Colorectal Cancer With Stratified Prognosis, Multi-Omics Landscape, Potential Mechanisms, and Treatment Options.
    Liu Z; Xu H; Weng S; Ren Y; Han X
    Front Immunol; 2022; 13():828330. PubMed ID: 35154148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel liver zonation phenotype-associated molecular classification of hepatocellular carcinoma.
    Zhang T; Gu J; Wang X; Lu Y; Cai K; Li H; Nie Y; Chen X; Wang J
    Front Immunol; 2023; 14():1140201. PubMed ID: 36936935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
    Yang L; Zhang W; Yan Y
    Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
    Wang J; Ling S; Ni J; Wan Y
    BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanylate-binding proteins signature predicts favorable prognosis, immune-hot microenvironment, and immunotherapy response in hepatocellular carcinoma.
    Ning Y; Fang S; Fang J; Lin K; Nie H; Xiong P; Qiu P; Zhao Q; Wang H; Wang F
    Cancer Med; 2023 Aug; 12(16):17504-17521. PubMed ID: 37551111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.
    Qu J; Sun F; Hou Y; Qi H; Sun X; Xing L
    BMC Cancer; 2023 Jun; 23(1):549. PubMed ID: 37322434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
    Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
    J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
    He Q; Yang J; Jin Y
    Front Immunol; 2022; 13():869993. PubMed ID: 35493518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy.
    Bu X; Liu S; Wen D; Kan A; Xu Y; Lin X; Shi M
    Mol Ther Oncolytics; 2022 Sep; 26():226-244. PubMed ID: 35919459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.